MovDisordV3, Main, Exploration, bibRecord, 004A02

Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what

Identifieur interne : 004A02 ( Main/Exploration ); précédent : 004A01; suivant : 004A03

Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what

Auteurs : Leo Verhagen Metman [États-Unis] ; Spiridon Konitsiotis [États-Unis] ; Thomas N. Chase [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2000-01.

RBID : ISTEX:28F504988C0ED13319B7D2062BFDC62D1DE5113D

English descriptors

KwdEn :
- Animals, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Corpus Striatum (drug effects), Corpus Striatum (physiopathology), Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Motor Skills (drug effects), Motor Skills (physiology), Neural Pathways (drug effects), Neural Pathways (physiopathology), Neurons (physiology), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Receptors, Dopamine (drug effects), Receptors, Dopamine (physiology), Receptors, N-Methyl-D-Aspartate (drug effects), Receptors, N-Methyl-D-Aspartate (physiology), Receptors, Presynaptic (drug effects), Receptors, Presynaptic (physiology), Substantia Nigra (drug effects), Substantia Nigra (physiopathology), Treatment Outcome.
MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , drug effects : Receptors, Dopamine, Receptors, N-Methyl-D-Aspartate, Receptors, Presynaptic.
- chemical , physiology : Receptors, Dopamine, Receptors, N-Methyl-D-Aspartate, Receptors, Presynaptic.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- diagnosis : Parkinson Disease.
- drug effects : Corpus Striatum, Motor Skills, Neural Pathways, Substantia Nigra.
- drug therapy : Parkinson Disease.
- physiology : Motor Skills, Neurons.
- physiopathology : Corpus Striatum, Neural Pathways, Parkinson Disease, Substantia Nigra.
- Animals, Humans, Treatment Outcome.

Url:

https://api.istex.fr/document/28F504988C0ED13319B7D2062BFDC62D1DE5113D/fulltext/pdf

DOI: 10.1002/1531-8257(200001)15:1<3::AID-MDS1003>3.0.CO;2-E

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what</title>
<author><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name>
</author>
<author><name sortKey="Konitsiotis, Spiridon" sort="Konitsiotis, Spiridon" uniqKey="Konitsiotis S" first="Spiridon" last="Konitsiotis">Spiridon Konitsiotis</name>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:28F504988C0ED13319B7D2062BFDC62D1DE5113D</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/1531-8257(200001)15:1<3::AID-MDS1003>3.0.CO;2-E</idno>
<idno type="url">https://api.istex.fr/document/28F504988C0ED13319B7D2062BFDC62D1DE5113D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003186</idno>
<idno type="wicri:Area/Istex/Curation">003186</idno>
<idno type="wicri:Area/Istex/Checkpoint">003202</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Metman L:pathophysiology:of:motor</idno>
<idno type="wicri:Area/Main/Merge">007299</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10634235</idno>
<idno type="wicri:Area/PubMed/Corpus">004068</idno>
<idno type="wicri:Area/PubMed/Curation">004068</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003F14</idno>
<idno type="wicri:Area/Ncbi/Merge">000183</idno>
<idno type="wicri:Area/Ncbi/Curation">000183</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000183</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Metman L:pathophysiology:of:motor</idno>
<idno type="wicri:Area/Main/Merge">007057</idno>
<idno type="wicri:Area/Main/Curation">004A02</idno>
<idno type="wicri:Area/Main/Exploration">004A02</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what</title>
<author><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Konitsiotis, Spiridon" sort="Konitsiotis, Spiridon" uniqKey="Konitsiotis S" first="Spiridon" last="Konitsiotis">Spiridon Konitsiotis</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-01">2000-01</date>
<biblScope unit="vol">15</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="3">3</biblScope>
<biblScope unit="page" to="8">8</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">28F504988C0ED13319B7D2062BFDC62D1DE5113D</idno>
<idno type="DOI">10.1002/1531-8257(200001)15:1<3::AID-MDS1003>3.0.CO;2-E</idno>
<idno type="ArticleID">MDS1003</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Corpus Striatum (drug effects)</term>
<term>Corpus Striatum (physiopathology)</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Motor Skills (drug effects)</term>
<term>Motor Skills (physiology)</term>
<term>Neural Pathways (drug effects)</term>
<term>Neural Pathways (physiopathology)</term>
<term>Neurons (physiology)</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Receptors, Dopamine (drug effects)</term>
<term>Receptors, Dopamine (physiology)</term>
<term>Receptors, N-Methyl-D-Aspartate (drug effects)</term>
<term>Receptors, N-Methyl-D-Aspartate (physiology)</term>
<term>Receptors, Presynaptic (drug effects)</term>
<term>Receptors, Presynaptic (physiology)</term>
<term>Substantia Nigra (drug effects)</term>
<term>Substantia Nigra (physiopathology)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term>
<term>Receptors, N-Methyl-D-Aspartate</term>
<term>Receptors, Presynaptic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Dopamine</term>
<term>Receptors, N-Methyl-D-Aspartate</term>
<term>Receptors, Presynaptic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term>
<term>Motor Skills</term>
<term>Neural Pathways</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Motor Skills</term>
<term>Neurons</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Corpus Striatum</term>
<term>Neural Pathways</term>
<term>Parkinson Disease</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name>
</region>
<name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<name sortKey="Konitsiotis, Spiridon" sort="Konitsiotis, Spiridon" uniqKey="Konitsiotis S" first="Spiridon" last="Konitsiotis">Spiridon Konitsiotis</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A02 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004A02 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:28F504988C0ED13319B7D2062BFDC62D1DE5113D
   |texte=   Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what

Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what

Source :

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.